A Phase I, Multicenter, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs HMPL A83 (Primary)
Indications Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions; First in man
Sponsors HUTCHMED

05 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 7 Jun 2025.
15 Jul 2022 Status changed from not yet recruiting to recruiting.
15 Jul 2022 According to Hutchmed media release, the first patient has been dosed with the study drug.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com